0001209191-19-014162.txt : 20190227 0001209191-19-014162.hdr.sgml : 20190227 20190227173015 ACCESSION NUMBER: 0001209191-19-014162 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190225 FILED AS OF DATE: 20190227 DATE AS OF CHANGE: 20190227 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Barth Jay CENTRAL INDEX KEY: 0001601896 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 19639076 MAIL ADDRESS: STREET 1: C/O AMICUS THERAPEUTICS, INC. STREET 2: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: (609) 662-2000 MAIL ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 FORMER COMPANY: FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC DATE OF NAME CHANGE: 20020729 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-02-25 0 0001178879 AMICUS THERAPEUTICS, INC. FOLD 0001601896 Barth Jay C/O AMICUS THERAPEUTICS, INC. 1 CEDAR BROOK DRIVE CRANBURY NJ 08512 0 1 0 0 Chief Medical Officer Common Stock 2019-02-25 4 M 0 26270 2.29 A 156037 D Common Stock 2019-02-25 4 S 0 26270 12.5162 D 129767 D Common Stock 2019-02-25 4 M 0 43730 2.94 A 173497 D Common Stock 2019-02-25 4 S 0 43730 12.5162 D 129767 D Common Stock 31 I by Daughter Stock Options (right to buy) 2.29 2019-02-25 4 M 0 26270 0.00 D 2024-03-03 Common Stock 26270 68730 D Stock Options (right to buy) 2.94 2019-02-25 4 M 0 43730 0.00 D 2024-06-26 Common Stock 43730 6270 D The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2018. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.50 to $12.58. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. All of the options were fully vested and exercisable as of February 25, 2019. /s/ Carol Welch, Attorney-in-Fact 2019-02-27